Navigation Links
New Precision Radiation Treatment System Fights Cancer
Date:8/26/2009

KANSAS CITY, Mo., Aug. 26 /PRNewswire/ -- Kansas City Cancer Center (KCCC), an affiliate of US Oncology, Inc. which supports the nation's foremost cancer treatment and research network, has treated its first patient with the new TomoTherapy(R) radiation therapy technology at its new KCCC-Shawnee Mission office.

KCCC is the only healthcare provider in the greater Kansas City metropolitan area with a TomoTherapy treatment machine - a welcomed new treatment that combines CT imaging with conformal radiation therapy. Used to treat a wide variety of cancers, KCCC's use of the TomoTherapy Hi Art((R)) treatment system is delivering radiation with pinpoint accuracy. According to Radiation Oncologist James Coster, M.D., this form of external beam radiation will protect patients from the harm that results from killing more than just the cancer.

"It's so precise that radiation can be localized to the cancer itself while nearly eliminating the dose to the surrounding healthy tissues," says Coster. "It completely changes the way we fight cancers of the head, neck, breast and prostate, and the impact we can make on overall patient health."

Protecting the health of surrounding tissue and organs has long been the goal of oncologists. But until now, technological limitations have prevented oncologists from delivering highly precise treatment specifically tailored to the patient's cancer, including the capacity to adapt the radiation to the cancer as it responds to treatment. With the Hi Art system, the equipment makes a 360-degree sweep of the patient, delivering intensity-modulated radiation therapy (IMRT) directly at the tumor. TomoTherapy treatment is performed with a patient lying on a special couch that moves through the center of the TomoTherapy unit as the radiation beam circles them. The result is a helical radiation treatment that delivers an optimized set of radiation beams to the tumor. Literally, the TomoTherapy process runs rings around cancer.

Before beginning a TomoTherapy treatment, KCCC uses 3D images from a combination of scanning technologies and special software to establish the precise contours for each tumor, and any regions at risk, such as sensitive organs or structures. The physician determines the radiation dose that will be given to the tumor, as well as acceptable levels for surrounding structures.

Each day before treatment, the Hi Art system allows doctors to take a CT scan to verify the position of the tumor. If necessary, the patient's position is adjusted to make sure radiation is directed at the tumor. This is critical, as the tumor can move as the patient moves.

Until now, the availability of TomoTherapy has been limited in this region, says Coster. KCCC is proud to add this new technology and its benefits to patients to its comprehensive suite of cancer treatment services.

About Kansas City Cancer Center

Kansas City Cancer Center is a full service cancer healthcare practice, with 11 offices throughout the region. KCCC provides a wide range of patient support, including oncology treatment, diagnostic imaging, genetic risk evaluation and testing, access to clinical trials and survivorship wellness services. Its patient-driven mission is to equip individuals and their families with everything they need to battle the disease, manage their care and navigate the insurance issues of a cancer diagnosis - all from a close-to-home environment. To learn more about KCCC, visit our website at www.KCCancercenter.com.

Kansas City Cancer Center is a member of the US Oncology network, which supports the nation's foremost cancer treatment and research network accelerating the availability and use of evidence-based medicine and shared best practices. With more than 1,227 physicians treating more than 650,000 patients at 468 locations, including 95 radiation oncology facilities, throughout 39 states, the US Oncology network and Kansas City Cancer Center provide cancer patients with access to the latest advancements in therapies, clinical research and technology, as well as best-in-class clinical and operational processes that help to advance the quality, safety and cost effectiveness of cancer care. For more information, visit the company's Web site, www.usoncology.com.

About TomoTherapy Incorporated

TomoTherapy Incorporated (Nasdaq: TOMO) has developed, markets and sells the TomoTherapy((R)) Hi Art((R)) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
2. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
3. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
4. Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
6. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
7. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
8. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
9. Precision Therapeutics President and CEO Sean McDonald Named Ernst & Young Entrepreneur of the Year(R) 2008 Regional Award Winner
10. Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance
11. Precision Therapeutics Secures $43 Million in Venture Capital Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... billing and coding services, and Deyta Analytics, recently announced the recipients of the ... level of quality as measured from the caregiver’s point of view. The official ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... use of Microsoft Dynamics GP for one their long-term care clients. Working together ... Dynamics GP with key clinical management systems, and delivered a fully integrated accounting ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society ... year, reproductive endocrinologists are required to report in vitro fertilization (IVF) ... dedicated to the practice of assisted reproductive technologies in the United States. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... BC and AD, saying it is time to set the record straight. Traditionally, BC ... this simply cannot possibly be true and offers explanation. , “To start with, the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
Breaking Medicine Technology: